Acute Acalculous Cholecystitis in a Child with COVID-19 and Influenza B: A Case Report
Abstract
Patient: Male, 7-year-old Final Diagnosis: Acute liver failure with acalculous cholecystitis likely caused by an Influenza B infection Symptoms: Abdominal pain • fever Clinical Procedure: — Specialty: Pediatrics and Neonatology Objective: Unusual clinical course Background Acute acalculous cholecystitis (AAC) is a rare pediatric condition marked by gallbladder inflammation without gallstones. In children, symptoms are non-specific, making diagnosis and management challenging. Imaging, particularly ultrasound or computed tomography (CT) scan, often is the key to detection. Treatment typically involves supportive care and antibiotics, with surgery reserved for severe cases. This report describes the case of a 7-year-old Malaysian boy with a history of COVID-19 and influenza B infection presenting with acute acalculous cholecystitis. Case Report A 7-year-old Malaysian boy presented with fever, vomiting, and abdominal pain, initially diagnosed as acute gastroenteritis at primary care clinic. As symptoms worsened, he went to the Emergency Department, where he tested positive for COVID-19 and influenza B and home quarantine was advised. He had another visit the next day in the same hospital and was given symptomatic treatment. On his fourth visit, due to worsening abdominal pain, he was found to have severe transaminitis and coagulopathy. A CT scan revealed AAC, which was managed conservatively. Treatment with intravenous immunoglobulin (IVIG) therapy led to marked clinical and…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.